Home » Stocks » INMB

Inmune Bio Inc. (INMB)

Stock Price: $7.66 USD -0.14 (-1.79%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $7.70 +0.04 (0.52%) Oct 30, 7:58 PM

Stock Price Chart

Key Info

Market Cap 103.01M
Revenue (ttm) n/a
Net Income (ttm) -9.56M
Shares Out 13.45M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $7.66
Previous Close $7.80
Change ($) -0.14
Change (%) -1.79%
Day's Open 7.84
Day's Range 7.28 - 7.84
Day's Volume 121,614
52-Week Range 2.20 - 24.42

More Stats

Market Cap 103.01M
Enterprise Value 98.35M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 13.45M
Float 6.69M
EPS (basic) -0.89
EPS (diluted) -0.89
FCF / Share -0.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 518,205
Short Ratio 3.41
Short % of Float 7.75%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.84
Revenue n/a
Operating Income -9.62M
Net Income -9.56M
Free Cash Flow -5.23M
Net Cash 4.66M
Net Cash / Share 0.35
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -23.77%
ROE -39.42%
ROIC -1,504.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(177.42% upside)
Current: $7.66
Target: 21.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-7.76-12.44-0.98-0.23
Net Income-7.68-12.44-0.83-0.28
Shares Outstanding10.278.686.565.00
Earnings Per Share-0.75-1.43-0.13-0.06
Operating Cash Flow-5.38-2.06-0.76-0.32
Free Cash Flow-5.38-2.06-0.76-0.32
Cash & Equivalents7.000.191.370.14
Total Debt0.17--0.35
Net Cash / Debt6.830.191.37-0.21
Book Value23.6116.5418.10-0.15
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inmune Bio Inc.
Country United States
Employees 4
CEO Raymond J. Tesi

Stock Information

Ticker Symbol INMB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INMB
IPO Date February 4, 2019


INmune Bio, a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.